Quarterly report · Q3
4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥683.0bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥239.1bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥618.0bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥214.7bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥105.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥39.0bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥93.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥105.7bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥39.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥92.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥79.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.8bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥1.69T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.54T | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥475.7bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.22T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.22T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.07T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥163.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥162.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥91.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥53.1bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥41.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥68.7bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥84.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥107.33 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥40.06 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥93.25 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥107.29 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥40.05 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.21 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥39.96 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.9% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.6% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-12-31 | ¥172m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥2.1bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥127.8bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥13.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥407.7bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥92.0bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥147.3bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥16.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥682.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥121.9bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-12-31 | ¥186m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥479m |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥113.4bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥358.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥83.6bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥145.5bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥617.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥109.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 653
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in deposits for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | － | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -12086000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -27864000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -31971000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -84450000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -68712000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 8626000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 6889000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -42863000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -23688000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 187322000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 162388000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 163633000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 358907000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 145511000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 113388000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 617807000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 186000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 617993000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 83598000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 12605000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 12924000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 109127000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | 479000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration | 109607000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -6770000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -7633000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReportableSegmentsMember | -14403000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReconcilingItemsMember | 4000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration | -14399000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YTDDuration | -1694000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 93514000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 1915000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 3466000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 136000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 92100000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 407700000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 147279000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 127799000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 682779000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | 172000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 682951000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 91992000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 15993000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 13869000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 121855000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -2121000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration | 119733000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |